Novo Nordisk seeks halt on compounded semaglutide

Pharmacy Board of Australia urged to restrict pharmacists from compounding semaglutide, despite supply shortages  Pharmaceutical manufacturer, Novo Nordisk, is raising safety concerns over pharmacists providing compounded semaglutide, the Australian Financial Review reports.  In a letter to the Pharmacy Board, Cem Ozem general manager for Oceania for Novo Nordisk – the maker of diabetes medication Ozempic

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous PSA seeks fresh funding for new pharmacy services
Next SA’s 24-7 pharmacy initiative launched